MetLife heads into the final stretch before its August 5 earnings print with the Street actively upgrading its view and the stock trading at a six-month high.
The analyst activity this week has been unusually concentrated. Morgan Stanley raised its target by $10 to $103 on July 6, keeping an Overweight rating. UBS followed on July 8, lifting its target to $105 from $102. Barclays also moved its target higher to $94. All three actions came within the past 48 hours, all maintained positive ratings, and none involved a downgrade. The consensus mean target now sits at $93.13 — roughly in line with the current $91.67 price — but the upper end of recent individual targets ($103–$105) suggests the bullish camp sees meaningful further room. The forward EPS momentum factor ranks in the 90th percentile of the universe, the clearest quantitative support for the bullish case. The PE multiple has edged lower over the past 30 days to 8.1x, making the valuation argument incrementally more attractive as the stock has moved.
Positioning in the lending market tells a story of near-zero short pressure. Availability is extraordinarily wide at roughly 9,900% — there are nearly 100 shares available to borrow for every one currently lent out — so there is no friction whatsoever for incremental shorts. Borrowing costs are negligible at 0.45% and have fallen roughly 21% on the week. Short interest at 2.2% of free float is low by any measure, and it has actually drifted lower over the past week after ticking up over the prior month. The ORTEX short score is stable in the mid-30s, having drifted gently lower from around 36.5 in late June. None of this suggests short sellers are building a meaningful thesis against the stock.
Options positioning is modestly defensive but not extreme. The put/call ratio is running at 1.34, a touch above its 20-day average of 1.30 and only 0.6 standard deviations above the mean — well short of the kind of elevated hedging one would associate with real uncertainty into earnings. The 52-week high on the PCR is 1.81, which puts the current reading in the lower half of the annual range. The options market, in other words, is not flagging unusual concern heading into August.
The earnings history offers some context worth noting. MetLife has fallen on the day of its last three quarterly prints — moves of -2.1%, -2.6%, and -1.4% respectively on the announcement day. The five-day reaction has been mixed, with one subsequent recovery and two continued declines. The pattern suggests the stock tends to fade on the event itself, even when underlying results are solid. The most recent note in the ORTEX commentary flags that Q2 beat estimates on both EPS and premium revenue, driven by group benefits and underwriting margins — yet the stock still moved lower on that date in June.
Among close peers, LNC gained 7.1% on the week and RGA rose 7.2%, both broadly in line with MET's 8.3% move. PRU added 5.7% and PRI 5.4%, suggesting the whole large-cap life insurance complex caught a bid. UNM was the notable laggard at -0.5% for the week. MetLife's outperformance versus UNM and its rough parity with LNC and RGA suggest sector tailwinds, rather than a company-specific catalyst, are the primary driver of the recent rally.
The setup heading into August 5 is a stock that has rallied sharply into earnings, with the Street actively lifting targets and the lending market entirely relaxed — the key question is whether the historical pattern of day-one fades reasserts itself, or whether the weight of analyst conviction this time carries through the print.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
